Sorrento Therapeutics Subsidiary, Scilex, Raises $140 million in Non-Dilutive Royalty-Based Financing

Sorrento Therapeutics (NASDAQ:SRNE) that its majority-owned subsidiary, Scilex Pharmaceuticals, closed a debt financing with leading global institutional investors for aggregate gross proceeds to Scilex of $140 million. As quoted in the press release: “This non-dilutive financing provides Scilex with the capital resources to successfully execute on the launch of ZTlido,” said Henry Ji, Chairman, President … Continued

The post Sorrento Therapeutics Subsidiary, Scilex, Raises $140 million in Non-Dilutive Royalty-Based Financing appeared first on Investing News Network.

Original Article: Sorrento Therapeutics Subsidiary, Scilex, Raises $140 million in Non-Dilutive Royalty-Based Financing

More From BioPortfolio on "Sorrento Therapeutics Subsidiary, Scilex, Raises $140 million in Non-Dilutive Royalty-Based Financing"

• Related Companies
• Related Clinical Trials
• Related PubMed Entries
• Related Medications